X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/immunic-receives-notice-of-allowance-for-united-states-patent-protecting-the-treatment-of-relapsing-multiple-sclerosis-with-vidofludimus-and-its-salts-301975455.html
https://www.prnewswire.com/news-releases/immunic-presents-data-from-phase-2-caldose-1-trial-of-vidofludimus-calcium-in-ulcerative-colitis-at-the-united-european-gastroenterology-week-2023-301956189.html
https://www.prnewswire.com/news-releases/immunic-completes-enrollment-of-its-phase-2-calliper-trial-of-vidofludimus-calcium-in-progressive-multiple-sclerosis-301903416.html
https://endpts.com/immunic-touts-positive-data-in-maintenance-phase-of-failed-phii-trial/
https://www.prnewswire.com/news-releases/immunic-reports-positive-data-from-maintenance-phase-of-phase-2-caldose-1-trial-of-vidofludimus-calcium-in-moderate-to-severe-ulcerative-colitis-301790538.html
https://www.prnewswire.com/news-releases/immunic-presents-data-from-phase-2-emphasis-trial-of-vidofludimus-calcium-in-relapsing-remitting-multiple-sclerosis-at-actrims-forum-2023-301751746.html
https://www.prnewswire.com/news-releases/immunic-reports-new-data-from-phase-2-emphasis-trial-of-vidofludimus-calcium-in-relapsing-remitting-multiple-sclerosis-supporting-the-drugs-neuroprotective-potential-301681124.html
https://www.fiercebiotech.com/biotech/after-ulcerative-colitis-flop-immunic-regains-some-momentum-multiple-sclerosis-update
https://endpts.com/immunic-shares-cut-in-half-as-biotech-dumps-ulcerative-colitis-after-phii-fail/
https://www.prnewswire.com/news-releases/immunic-inc-reports-top-line-data-from-phase-2-caldose-1-trial-of-vidofludimus-calcium-in-patients-with-moderate-to-severe-ulcerative-colitis-and-provides-corporate-update-301559930.html
https://www.prnewswire.com/news-releases/immunic-inc-announces-enrollment-of-first-patient-in-its-phase-3-ensure-program-of-vidofludimus-calcium-imu-838-in-relapsing-multiple-sclerosis-301428570.html
Market Place
Share 
